Drug Trial Radar · NCT02735421
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
May 13, 2016
Primary completion
Jun 5, 2017
Study completion Nov 23, 2017
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 16 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multi-centre, randomized, investigator blinded, vehicle controlled trial using intra-individual comparison (right half-face versus left half-face). Participants with each half-face randomized to one of the two following treatments: * Adapalene 0.3 percent (%) - benzoyl peroxide (BPO) 2.5% gel (TactuPump® Forte). * Vehicle gel The main objective of this trial was to evaluate the effect of Adapalene 0.3% - BPO 2.5% (ABPO Forte) gel versus vehicle gel on the risk of formation of atrophic acne scars in moderate to severe acne participants.
Conditions
- Acne Vulgaris
- Atrophic Acne Scars
Interventions
ABPO Forte GelDrug
Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
Vehicle gelDrug
Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Total Atrophic Acne Scar Count Per Half-faceTime frame: Week 24
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Markham, Ontario, Canada
Site not named
Oakville, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Windsor, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Saint-Jérôme, Quebec, Canada
Site not named
Nantes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.